Iris Dorbian

Atlantic Therapeutics snags Series B funding

Atlantic Therapeutics, a medical technology company focused on treating bladder leaks, has secured 28 million euros in Series B funding. LSP led the round with participation from other investors that included Andera Partners, Atlantic Bridge Ventures, Seroba Life Sciences and Earlybird Venture Capital.

Aerospace startup Boom Supersonic gathers $100 mln Series B

Denver-based Boom Supersonic, an aerospace startup, has raised $100 million in Series B funding. The investors included Sunstone Management and Y Combinator Continuity.

Third Kind Venture Capital targets $65 mln for sophomore fund

Third Kind Venture Capital is seeking to raise $65 million for its second fund, according to an SEC filing. The New York-based venture firm is focused on early-stage investments.

Qualcomm Ventures backs Baicells

Plano, Texas-based Baicells, a small cell technology company, has secured an undisclosed amount of funding. The investor was Qualcomm Ventures LLC.

Medication guidance company WithMe Health rakes in $20 mln

Boston-based WithMe Health, a medication guidance company, has raised $20 million in financing. The investor was Oak HC/FT.

Pear Therapeutics locks in $64 mln Series C

Boston and San Francisco-based Pear Therapeutics, a provider of prescription digital therapeutics, has secured $64 million in Series C financing. Temasek led the round with participation from other investors that included Novartis, 5AM Ventures, Arboretum Ventures, Jazz Venture Partners, The Bridge Builders Collaborative, EDBI, Blue Water Life Science Fund LP and Trustbridge Partners.

Ribon Therapeutics lands $65 mln Series B

Lexington, Massachusetts-based Ribon Therapeutics, a biotechnology company, has raised $65 million in Series B financing. Novartis Venture Fund led the round with participation from JJDC, Celgene Corporation, The Column Group, Deerfield Management, U.S. Venture Partners, Osage University Partners, Takeda Ventures and Euclidean Capital.

Swiss health tech company Sophia Genetics picks up $77 mln

Sophia Genetics, a Swiss health tech company, has raised $77 million in funding. Generation Investment Management led the round with participation from other investors that included Idinvest Partners, Balderton Capital and Alychlo.

Oculis nets about $15.6 mln

Oculis, a Swiss developer of ophthalmic drugs, has raised CHF 15.5 million (about $15.6 million) in funding. Tekla Capital Management LLC led the round with participation from other investors that included Nan Fung Life Sciences.

Cell therapy company Immusoft inks $20 mln Series B

Seattle-based Immusoft Corporation, a cell therapy company, has raised $20 million in Series B financing. The investors included Breakout Ventures, Alexandria Venture Investments, RBV Capital, DEFTA Partners and Mesa Verde Venture Partners.